This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EpCAM IgG-ala to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EpCAM as well as the biological activity of IL2. Ig-IL2 fusion protein containing the D20T mutation has a drastically reduced potency in activation of IL2R-βγ-bearing cells, but has essentially normal potency in activating IL-2Rαβγ-bearing cells. This immunocytokine was designed for treating solid tumor.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-112-F(E) | Anti-Human EpCAM Recombinant Antibody Fab Fragment, 17-1A (Citatuzumab Bogatox) | Neut, ELISA, IF, IP, FuncS, FC, ICC | Fab - G1 - kappa |
TAB-362MZ-S(P) | Anti-Human EPCAM Recombinant Antibody scFv Fragment (3622W94) | Confocal, ELISA | Humanized antibody |
TAB-374MZ-S(P) | Anti-Human EPCAM Recombinant Antibody scFv Fragment (h12H8B) | FC, ELISA | Humanized antibody |
TAB-375MZ-S(P) | Anti-Human EPCAM Recombinant Antibody scFv Fragment (h12H8C) | FC, ELISA | Humanized antibody |
TAB-376MZ-S(P) | Anti-Human EPCAM Recombinant Antibody scFv Fragment (h2D11B) | FC, ELISA | Humanized antibody |
There are currently no Customer reviews or questions for ACFP-SH145. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.